InvestmentMay 21, 2026, 08:32 AM
Akari Therapeutics Prices $5.5M Private Placement
AI Summary
Akari Therapeutics Plc successfully priced a private placement financing round, expected to raise approximately $5.5 million in gross proceeds. These funds will primarily advance its lead ADC program, AKTX-101, towards a first-in-human Phase 1 clinical trial, and for general corporate purposes. The transaction involves the issuance and sale of 1,470,588 unregistered ADSs (or prefunded warrants) priced at $3.74 per ADS, along with unregistered Series H, I, and J Warrants, subject to shareholder approval. The gross proceeds will be funded in three separate closings between May 27, 2026, and July 15, 2026.
Key Highlights
- Private placement expected to raise approximately $5.5 million in gross proceeds.
- Offering includes 1,470,588 unregistered American Depository Shares (ADSs) or prefunded warrants.
- ADSs were priced at $3.74 per ADS.
- Series H, I, and J Warrants will each be exercisable for 1,470,588 ADSs.
- Series H, I, and J Warrants have an exercise price of $3.74 per ADS.
- Gross proceeds to be funded in three tranches between May 27, 2026, and July 15, 2026.
Price Impact
More from AKTX